TradeLink Capital’s Sage Therapeutics SAGE Stock Holding History

TradeLink Capital’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-2,000	Closed	-$318K	–	33
2019 Q1	$318K	Buy	+2,000	New	+$290K	1.69%	26

Other funds holding SAGE

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

TradeLink Capital's SAGE Position: Q2 2019 in Review

TradeLink Capital sold out of Sage Therapeutics (SAGE) in Q2 2019, closing a stake of 2,000 shares — an estimated $318K sold.

TradeLink Capital first reported a position in SAGE in Q1 2019 and held it in 1 quarter. The position peaked at $318K in Q1 2019. 272 funds tracked by Wall St. Rank hold SAGE as of Q2 2019.

TradeLink Capital reported no remaining Sage Therapeutics position as of Q2 2019 after selling out during the quarter.
TradeLink Capital sold 2,000 Sage Therapeutics shares in Q2 2019, an estimated $318K.
TradeLink Capital first reported a position in Sage Therapeutics in Q1 2019 and held it in 1 quarter.
TradeLink Capital's Sage Therapeutics position peaked at $318K in Q1 2019.
272 funds tracked by Wall St. Rank held Sage Therapeutics as of Q2 2019.

Based on TradeLink Capital's 13F filing for Q2 2019, filed 31 Jul 2019.